Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
REFERENCES
1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997;46(No. RR-12).
2. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 & infected compartments during combination therapy. Nature 1997;387:188 & 91.
3. Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992;165:352 & 63. 4. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the international AIDS Society—USA panel. JAMA 1997;277:1962 & 9.
5. Raboud JM, Montaner JSG, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996;174:191 & 4.
6. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(No. RR-17).
7. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185 & 91.
8. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990;112:727 & 37.
9. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941 & 9.
10. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437 & 42.
11. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081 & 90.
12. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946 & 54.
13. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411 & 9.
14. Keulen W, Back NKT, van Wijk A, et al. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997;71:3346 & 50.
15. CDC. Clinical update—impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996;45:921 & 5.
16. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257 & 64.
17. Kinloch de Loës S, de Saussure P, Saurat J, Stalder H, Hirschel B, Perrin, LH. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis 1993;17:59 & 65.
18. Tindall B, Cooper D. Primary HIV infection: host responses and intervention strategies. AIDS 1991;5:1 & 14.
19. Niu MJ, Stein D, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993;168:1490 & 501.
20. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175:1051 & 5.
21. CDC. Update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468 & 72.
22. Hoen B, Harzic M, Fleury HF, et al. ANRS053 trial of zidovudine (ZDV), lamivudine (3TC), and ritonavir combination in patients with symptomatic primary HIV-1 infection: preliminary results [Abstract 232]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: January 22 & 26, 1997.
23. Tamalet C, Poizot Martin IP, Lafeuillade A, et al. Viral load and genotypic resistance pattern in HIV-1 infected patients treated by a triple combination therapy including nucleoside and protease inhibitors (NIS and PIS) initiated at primary infection [Abstract 592]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: January 22 & 26, 1997.
24. Perrin L, Markowitz M, Calandra G, Chung M, and the MRL Acute HIV Infection Study Group. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate [Abstract 238]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: January 22 & 26, 1997.
25. Minkoff H, Augenbraun M: Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997;176:478 & 89.
26. CDC. Pregnancy outcomes following systemic prenatal acyclovir exposure—June 1, 1984 & June 30, 1993. MMWR 1993;42:806 & 9.
27. O’Sullivan MJ, Boyer PJJ, Scott GB, et al: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993;168:1510 & 6.
28. Moodley J, Moodley D, Pillay K, et al: Antiviral effect of lamivudine alone and in combination with zidovudine in HIV-infected pregnant women [Abstract 607]. In: Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: January 22 & 26, 1997.
29. Sandberg JA, Slikker W: Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides. FASEB J. 1995;9:1157 & 63.
30. FDA Public Health Advisory: Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). JAMA 1997;278:379.
31. CDC. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998;47(RR-2).
32. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621 & 9.
33. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal genotypic zidovudine (ZDV) resistance and failure of ZDV therapy to prevent mother-child HIV-1 transmission [Abstract 516]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: January 22 & 26, 1997.
34. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725 & 33.
35. Gulick RM, Mellors JW, Havlir D, et AL. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734 & 9.
36. de Jong MD, Vella S, Carr A, et al: High-dose nevirapine in previously untreated human immunodeficiency virus type-1 & infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966 & 70.
37. Schapiro JM, Winters MA, Stewart F, et al: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039 & 50.
38. Bartlett JG: Protease inhibitors for HIV infection. Ann Intern Med 1996;124:1086 & 8.
39. Eron JT, Benoit SL, Jemsek J, et al: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662 & 9.
40. Staszewski S, Loveday C, Picazo JJ, et al: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA 1996;276:111 & 7.
41. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia (letter). Lancet 1997;350:713 & 4.
42. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy (letter). Ann Intern Med 1997;127:947.
43. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor (letter). Ann Intern Med 1997;127:948.
44. Hanson C, Cooper E, Antonelli T, et al: Lack of tumors in infants with perinatal HIV exposure and fetal/neonatal exposure to zidovudine (AZT) [Abstract 304.3]. In: Proceedings of the National Conference on Women and HIV. Pasadena, CA: May 4 & 7, 1997.
Go to the NIH Report & Guidelines Menu
Go to the HIVpositive.us Main Menu